XyCAD-MMG

Xylexa detects breast cancer at an earlier stage, improving a patient’s chances of survival while making interventional treatments more effective and less intense.

Play Video

How it works ...

Improved Productivity

Workflow automation where AI supported studies get acquired from either the imaging modality or the PACS into XyCAD for AI processing.

AI Analytics & Results‚Äč

Xylexa’s AI algorithm automatically marks regions of interest whether they be suspicious for calcifications and/or soft tissue lesions, even before a Radiologist pulls up a study for interpretation.

Clinical Benefits

Decision making with confidence

Xylexa empowers Radiologists to deliver improved clinical insights for their patients via use of XyCAD-MMG.

Xylexa empowers Radiologists to deliver improved clinical insights for their patients via use of XyCAD-MMG.

Multi-model SaMD

Detection, localization, & classification of both mass and calcifications.

Decision-making

Acts either as an independent first or second reader, a concurrent reader, or supports a double reader configuration.

Operational Efficiency

XyCAD-MMG detects & marks ROIs for both mass & calcifications, enhancing Radiologists' accuracy & productivity.

Workflow Efficiency

Ubiquitous access of PACS, DICOM, and AI analytics anywhere, on any device, anytime, conveniently.

Image Interpretation Efficiency

Up to 25% reduction in image interpretation, decision making, and reporting time.

Diagnostic Efficiency

XyCAD-MMG boosts Radiologist accuracy by up to 19% in interpreting mammograms in clinical settings.

Clinically Validated

Improved Diagnostic Accuracy

XyCAD-MMG has been clinically evaluated and validated by qualified Radiologists at multiple hospitals and radiology imaging facilities, and is FDA 510(k) pending.

Sensitivity
0 %
Specificity
0 %
auc - roc
0 %